AVITA Medical, Inc. (NASDAQ: RCEL) reported Q2 EPS of ($0.25), $0.05 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.7 million versus the consensus estimate of $20.08 million.

GUIDANCE:

AVITA Medical, Inc. sees FY2026 revenue of $86-89 million, versus the consensus of $83.09 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.